Your browser doesn't support javascript.
loading
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.
Yazici, Yusuf; Xie, Lin; Ogbomo, Adesuwa; Ellis, Lorie A; Goyal, Kavitha; Teeple, Amanda; Mutlu, Ece A; Simsek, Ismail.
Affiliation
  • Yazici Y; Department of Internal Medicine, Division of Rheumatology, New York University Hospital for Joint Diseases, New York, NY, USA.
  • Xie L; STATinMED Research, Health Economics and Outcomes Research, Ann Arbor, MI, USA, aogbomo@statinmed.com.
  • Ogbomo A; STATinMED Research, Health Economics and Outcomes Research, Ann Arbor, MI, USA, aogbomo@statinmed.com.
  • Ellis LA; Janssen Scientific Affairs, Real World Value and Evidence, Titusville, NJ, USA.
  • Goyal K; Janssen Biotech Incorporated, Immunology Medical Affairs, Horsham, PA USA.
  • Teeple A; Jassen Scientific Affairs, LLC, Health Economics and Outcomes Research, Horsham, PA, USA.
  • Mutlu EA; Rush University, Medical College, Department of Medicine, Chicago, IL, USA.
  • Simsek I; Guven Hospital, Department of Rheumatology, Ankara, Turkey.
Biologics ; 12: 97-106, 2018.
Article de En | MEDLINE | ID: mdl-30323555
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Biologics Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Biologics Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique